Clinical Research Directory

Inclusion Criteria: * Participant must be over 18 years of age. * Participant is able and willing to provide written informed consent which includes compliance with and ability to undergo all study procedures and attend the scheduled follow-up visits per protocol. * Either locally advanced or borderline resectable pancreatic adenocarcinoma, as confirmed by diagnostic images (CT, MRI or PET-CT scan) and based on vessel involvement according to the NCCN guidelines. Only borderline resectable pancreatic cancer (BRPC) patients who are medically unfit for surgery or refusing surgery can be included. * Adequate organ function determined by the following laboratory values: * Adequate bone marrow function: absolute neutrophil count ≥1500/mm\^3, platelet count ≥100000/mm\^3 and hemoglobin ≥9 g/dl * Adequate renal function: Creatinine ≤1.5 x upper normal limit of normal (ULN) or estimated eGFR more than 45 ml/min * Adequate liver function: total bilirubin ≤1.5 ULN (after adequate biliairy stenting with metal stent) and alanine aminotransferase (ALT) ≤5x ULN * An Eastern Cooperative Oncology Group (ECOG) performance status grade of 0-2. * A life expectancy ≥3 months * A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: * Is not a woman of child bearing potential or * A woman of child bearing potential must have a negative serum pregnancy test at screening and must use a very effective method of birth control. Exclusion Criteria: * Extrapancreatic metastatic disease as defined on diagnostic imaging (CT, MRI or PET-CT scan) or laparoscopy, including distal nodal involvement beyond the peripancreatic tissues and/or distant metastases. * Massive gastric or intestinal invasion as assessed on imaging and/or endoscopy. Direct invasion of the duodenal mucosa as visible on endoscopic ultrasound (EUS). * Prior radiation therapy that could hamper adequate dose delivery * Contraindication to magnetic resonance imaging (MRI) * Diagnosis of another malignancy within 2 years prior to randomization, except non-melanoma skin cancer, non-invasive bladder cancer, carcinoma in situ of the cervix or non-metastatic prostate cancer. Patients with a history of other malignancies are eligible if they have been continuously disease-free for at least 2 years after definitive primary treatment. * Any condition for which, in the opinion of the Investigator, participation would not be in the best interest of the subject. * Patient already included in another clinical trial that would interfere with the TORPEDO clinical trial, as assessed by the Investigator. * Known presence of an active ulcer (i.e. detected during standard of care diagnostic assessments) Additional exclusion criteria after restaging (i.e. within 1 week after 3 months of induction chemotherapy) and prior to randomization: * Extrapancreatic metastatic disease as defined on diagnostic imaging, including distal nodal involvement beyond the peripancreatic tissues and/or distant metastases * Massive gastric or intestinal invasion as assessed on imaging and/or endoscopy. Direct invasion of the duodenal mucosa as visible on EUS. * Known presence of an active ulcer (i.e. detected during standard of care diagnostic assessments)